Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.430
-0.020 (-1.38%)
At close: Aug 1, 2025, 4:00 PM
1.480
+0.050 (3.50%)
After-hours: Aug 1, 2025, 7:21 PM EDT

Company Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada.

The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil.

Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals logo
CountryCanada
Founded2003
IndustryBiotechnology
SectorHealthcare
Employees33
CEOJoseph Oliveto

Contact Details

Address:
1111 Dr. Frederik-Philips Boulevard, Suite 420
Montreal, QC H4M 2X6
Canada
Phone514-336-0444
Websitemilestonepharma.com

Stock Details

Ticker SymbolMIST
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001408443
CUSIP Number59935V107
ISIN NumberCA59935V1076
SIC Code2834

Key Executives

NamePosition
Joseph G. Oliveto M.B.A.Chief Executive Officer, President and Director
Amit HasijaChief Financial Officer and Executive Vice President of Corporate Development
Dr. David B. Bharucha FACC, M.D., Ph.D.Chief Medical Officer
Dr. Philippe Douville M.B.A., Ph.D.Founder, Strategic Advisor and Member of Scientific Advisory Board
Jeffrey NelsonChief Operating Officer
Roshan GirglaniVice President of Marketing
Jeff MooreVice President of Sales
Dr. Philip T. Sager FACC, FAHA, FHRS, M.D.Chief Medical Advisor and Member of the Scientific Advisory Board
Dr. Guy RousseauSVice President of Regulatory Affairs and Quality Management
Lorenz MullerChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Jul 21, 2025SCHEDULE 13GFiling
Jul 14, 20258-KCurrent Report
Jul 14, 2025424B5Filing
Jul 11, 2025424B5Filing
Jul 11, 20258-KCurrent Report
Jun 16, 20258-KCurrent Report
Jun 12, 20258-KCurrent Report
May 14, 20258-KCurrent Report
May 14, 202510-QQuarterly Report
Apr 30, 2025ARSFiling